Trial Profile
Effect of Erdosteine on inflammatory and oxidative biomarkers in sputum and exhaled breath in patients with COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Erdosteine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Biomarker; Therapeutic Use
- 27 Jul 2019 Status changed from recruiting to completed.
- 28 Aug 2011 New trial record